Literature DB >> 25804274

Coffee but not green tea consumption is associated with prevalence and severity of hepatic steatosis: the impact on leptin level.

T Imatoh1, S Kamimura2, M Miyazaki3.   

Abstract

BACKGROUND/
OBJECTIVES: Most of the studies that have investigated the association between coffee consumption and hepatic steatosis have been experimental and small-scale clinical studies. As a result, epidemiological studies are scarce. To clear the association, we conducted a cross-sectional study and investigated the effects of coffee consumption with those of green tea consumption. SUBJECTS/
METHODS: We analyzed 1024 Japanese male workers. The diagnosis of hepatic steatosis was based on ultrasonography. We divided coffee and green tea consumption into the following three categories: non-drinker; 1-2 cups/day and ⩾3 cups/day. To investigate the association between hepatic steatosis and coffee or green tea consumption, we calculated the odds ratio (OR) and adjusted the means of leptin levels on each severity of hepatic steatosis.
RESULTS: A total of 265 of our subjects (25.9%) were diagnosed with hepatic steatosis. The ORs of the group of subjects who drank >3 cups of coffee/day was significantly lower compared with that of the noncoffee drinker group (OR 0.59, 95% confidence intervals 0.38-0.90, P=0.03). Although there was a significant difference between coffee consumption and leptin level only in the asymptomatic group, we found a decreasing trend in the asymptomatic and moderate-severe hepatic steatosis group. We did not find the same relationships in green tea consumption.
CONCLUSIONS: Although we did not find an association between hepatic steatosis and green tea consumption, coffee may have beneficial effects on hepatic steatosis. In addition, we produced one possible hypothesis that coffee consumption negatively associates with leptin levels in hepatic steatosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25804274     DOI: 10.1038/ejcn.2015.23

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  29 in total

1.  Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice.

Authors:  Ryan N Fiorini; Jennifer L Donovan; David Rodwell; Zachary Evans; Gang Cheng; Harold D May; Charles E Milliken; John S Markowitz; Crystal Campbell; Julia K Haines; Michael G Schmidt; Kenneth D Chavin
Journal:  Liver Transpl       Date:  2005-03       Impact factor: 5.799

Review 2.  Tea and cancer prevention: epidemiological studies.

Authors:  Jian-Min Yuan; Canlan Sun; Lesley M Butler
Journal:  Pharmacol Res       Date:  2011-03-23       Impact factor: 7.658

3.  Proinflammatory adipokine leptin mediates disinfection byproduct bromodichloromethane-induced early steatohepatitic injury in obesity.

Authors:  Suvarthi Das; Ashutosh Kumar; Ratanesh Kumar Seth; Erik J Tokar; Maria B Kadiiska; Michael P Waalkes; Ronald P Mason; Saurabh Chatterjee
Journal:  Toxicol Appl Pharmacol       Date:  2013-02-22       Impact factor: 4.219

4.  Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis.

Authors:  Jeffrey W Molloy; Christopher J Calcagno; Christopher D Williams; Frances J Jones; Dawn M Torres; Stephen A Harrison
Journal:  Hepatology       Date:  2011-12-22       Impact factor: 17.425

Review 5.  Green tea consumption and liver disease: a systematic review.

Authors:  Xi Jin; Ruo-heng Zheng; You-ming Li
Journal:  Liver Int       Date:  2008-05-15       Impact factor: 5.828

6.  Coffee consumption delays the hepatitis and suppresses the inflammation related gene expression in the Long-Evans Cinnamon rat.

Authors:  Masafumi Katayama; Kenichiro Donai; Hiroyuki Sakakibara; Yukiko Ohtomo; Makoto Miyagawa; Kengo Kuroda; Hiroko Kodama; Kazufumi Suzuki; Noriyuki Kasai; Katsuhiko Nishimori; Takafumi Uchida; Kouichi Watanabe; Hisashi Aso; Emiko Isogai; Hideko Sone; Tomokazu Fukuda
Journal:  Clin Nutr       Date:  2013-05-17       Impact factor: 7.324

7.  Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.

Authors:  Jia Xiao; Chi Tat Ho; Emily C Liong; Amin A Nanji; Tung Ming Leung; Thomas Yue Huen Lau; Man Lung Fung; George L Tipoe
Journal:  Eur J Nutr       Date:  2013-03-21       Impact factor: 5.614

Review 8.  Coffee, caffeine, and coronary heart disease.

Authors:  Marilyn C Cornelis; Ahmed El-Sohemy
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2007-11       Impact factor: 4.294

9.  High Fat Diet Induces Liver Steatosis and Early Dysregulation of Iron Metabolism in Rats.

Authors:  Rosaria Meli; Giuseppina Mattace Raso; Carlo Irace; Raffaele Simeoli; Antonio Di Pascale; Orlando Paciello; Teresa Bruna Pagano; Antonio Calignano; Alfredo Colonna; Rita Santamaria
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

10.  Association of coffee consumption with serum adiponectin, leptin, inflammation and metabolic markers in Japanese workers: a cross-sectional study.

Authors:  K Yamashita; H Yatsuya; T Muramatsu; H Toyoshima; T Murohara; K Tamakoshi
Journal:  Nutr Diabetes       Date:  2012-04-02       Impact factor: 5.097

View more
  3 in total

Review 1.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 2.  The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.

Authors:  Erica Jennison; Christopher D Byrne
Journal:  Clin Mol Hepatol       Date:  2020-12-10

Review 3.  Coffee Consumption and Non-alcoholic Fatty Liver Disease: An Umbrella Review and a Systematic Review and Meta-analysis.

Authors:  Chayanis Kositamongkol; Sukrit Kanchanasurakit; Chiraphong Auttamalang; Nutkamon Inchai; Thanatchaporn Kabkaew; Sarunporn Kitpark; Nathorn Chaiyakunapruk; Acharaporn Duangjai; Surasak Saokaew; Pochamana Phisalprapa
Journal:  Front Pharmacol       Date:  2021-12-13       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.